As part of Parkinson's disease Awareness Month, we’re highlighting information resources on Parkinson's disease.
One of the most consulted topics by patients who visit The Neuro-Patient Resource Centre is about driving. It’s a topic that brings up a lot of questions and uncertainties.
The resource we use regularly is the @Parkinson Quebec web page, a reliable source that addresses common concerns such as:
One of the things that makes developing effective treatments for Parkinson’s disease so challenging is its complexity. While some forms are caused by genetics, others have environmental factors, and patients can show a wide range of symptoms of varying severity. Diagnosis of Parkinson’s is also currently made very late, after the disease may have been in the brain for a decade or more.
People with rapid eye movement (REM) sleep behavior disorder act out their dreams. While sleeping safely in bed, for example, they might throw up their arms to catch an imaginary ball, or try to run from an illusory assailant. Such actions are more than just a nuisance. People with the disorder have a 50 to 80 per cent chance of developing a serious neurodegenerative disease within a decade of diagnosis.
Large international study will help select and categorize patients for better clinical trials
A large multi-centre study of more than 1,200 patients provides important predictors of Parkinson’s disease progression, which will allow better candidate selection for clinical trials and more effective therapy development.
A team of Canadian scientists, including researchers at the Montreal Neurological Institute and Hospital (The Neuro), has discovered the first French-Canadian founder mutation gene linked to synucleinopathies, a group of neurodegenerative diseases that includes Parkinson’s disease (PD), dementia with Lewy-Bodies (DLB) and multiple system atrophy (MSA).
Carriers at higher risk of developing neurodegenerative disease
A team of Canadian scientists, including researchers at the Montreal Neurological Institute and Hospital (The Neuro) has discovered the first French-Canadian founder mutation gene linked to synucleinopathies, a group of neurodegenerative diseases that includes Parkinson’s disease (PD), dementia with Lewy-Bodies (DLB) and multiple system atrophy (MSA).
A new study, published today in Nature Structural & Molecular Biology, moves researchers closer to understanding one of the crucial proteins involved in Parkinson’s disease.
For someone with Parkinson’s disease (PD), the simple desire to grasp a glass of water can become an insurmountable task, made impossible by the tremors in their hand or arm. Finding strategies to improve these movement impairments is one of the major goals of rehabilitating people with Parkinson’s disease.
At McGill University, Dr. Marc Roig, an assistant professor in the School of Physical and Occupational Therapy (SPOT), is studying the effects of using high-intensity exercise to stimulate the brain’s ability to learn and change with repeated experiences.
April is Parkinson’s Awareness Month, a time to give special attention to a disease that affects approximately 100,000 Canadians. As a centre for both research and clinical treatment of Parkinson’s disease (PD), the Montreal Neurological Institute and Hospital (The Neuro) offers many specialized services and opportunities to participate in research to PD patients.
Industry and academia to share expertise in effort to develop improved methods to produce and characterize antibodies and reagents for neurological research
A team of scientists led by Dr. Michel Desjardins from the University of Montreal and Dr. Heidi McBride from the Montreal Neurological Institute and Hospital (MNI) at McGill University have discovered that two genes associated with Parkinson's disease (PD) are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease.
Using both cellular and mouse models, the team has shown that proteins produced by the two genes, known as PINK1 and Parkin, are required to prevent cells from being detected and attacked by the immune system.
The results of their study, published in the journal Movement Disorders, could also have a major impact on the quality of research on Parkinson’s disease.
Dancing the Argentine tango could have potential benefits for people at certain stages in the development of Parkinson’s disease (PD), according to findings in a new study by researchers at the Montreal Neurological Institute and Hospital -The Neuro, McGill University and the Research Institute of the McGill University Health Centre.
New study puts 40 patients through 12-week course
Dancing the Argentine tango could have potential benefits for people at certain stages in the development of Parkinson’s disease (PD), according to findings in a new study by researchers at the Montreal Neurological Institute and Hospital -The Neuro, McGill University and the Research Institute of the McGill University Health Centre. The study looked at changes in patients’ motor abilities following a 12-week tango course, and is also the first study to assess the effect that tango has on non-motor symptoms.
